: a promising biomarker in clear cell renal cell carcinoma.

Background: Aurora kinase B () is an important carcinogenic factor in various tumors, while its role in clear cell renal cell carcinoma (ccRCC) still remains unclear. This study aimed to investigate its prognostic value and mechanism of action in ccRCC.

Methods: Gene expression profiles and clinical data of ccRCC patients were downloaded from The Cancer Genome Atlas database. R software was utilized to analyze the expression and prognostic role of in ccRCC. Gene set enrichment analysis (GSEA) was used to analyze related signaling pathways in ccRCC.

Results: was expressed at higher levels in ccRCC tissues than normal kidney tissues. Increased expression in ccRCC correlated with high histological grade, pathological stage, T stage, N stage and distant metastasis (M stage). Kaplan-Meier survival analysis suggested that high expression patients had a worse prognosis than patients with low expression levels. Multivariate Cox analysis showed that expression is a prognostic factor of ccRCC. GSEA indicated that genes involved in autoimmune thyroid disease, intestinal immune network for IgA production, antigen processing and presentation, cytokine-cytokine receptor interaction, asthma, etc., were differentially enriched in the high expression phenotype.

Conclusions: is a promising biomarker for predicting prognosis of ccRCC patients and a potential therapeutic target. In addition, might regulate progression of ccRCC through modulating intestinal immune network for IgA production and cytokine-cytokine receptor interaction, etc. signaling pathways. However, more research is necessary to validate the findings.